Last Update: Aug 27, 2026 A Phase I, Open Label First in Human Study to Evaluate the Imaging Performance, Safety, Biodistribution and Pharmacokinetics of [68Ga]Ga-DWJ155 in Adult Patients With Advanced Breast Cancer and Advanced NSCLC ClinicalTrials.gov Identifier: [NCT07117214](https://clinicaltrials.gov/ct2/show/NCT07117214) Novartis Reference Number:CFKL480A02101 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description This is a phase I, open label first in human study to evaluate the imaging performance, safety, biodistribution and pharmacokinetics of \\\[68Ga\\\]Ga-DWJ155 in patients ≥ 18 years of age with hormone receptor positive/HER2 negative (HR+/HER2-) and HER2 positive (HER2+) advanced breast cancer (aBC) and advanced Non-Small Cell Lung Cancer (aNSCLC) adenocarcinoma. This is a first-in-human (FIH), open-label, phase I radioligand imaging study designed to assess the biodistribution, imaging, safety, PK and dosimetry properties in patients with aBC and aNSCLC adenocarcinoma. Approximately 15-21 aBC and 9-15 aNSCLC patients will be enrolled into the study. All patients enrolled in the study will receive a single administered radioactive dose of FKL480. The study will consist of an imaging characterization part and an expansion part. Condition Breast Neoplasms, Carcinoma, Non-Small-Cell Lung Phase Phase1 Overall Status Recruiting Number of Participants36 Start Date Jun 26, 2026 Completion Date Jan 26, 2029 Gender All Age(s) 18 Years - 100 Years (Adult, Older Adult) ## Interventions Drug ### \[68Ga\]Ga-DWJ155 Radioligand imaging agent ## Eligibility Criteria Inclusion Criteria: \* Age ≥ 18 years old \* Patients with histologically or cytologically confirmed and documented HR+/HER2- advanced breast cancer (aBC), advanced defined as locoregionally advanced unresectable or metastatic, either untreated or currently receiving first line of systemic therapy OR patients with histologically or cytologically confirmed and documented HER2+ aBC, advanced defined as locoregionally advanced unresectable or metastatic, either untreated or relapsed/refractory (r/r) after one or more lines of treatment OR patients with histologically or cytologically confirmed and documented advanced NSCLC (aNSCLC) adenocarcinoma, advanced defined as locoregionally unresectable or metastatic, either untreated or currently receiving first line of systemic therapy. \* Presence of measurable disease (at least one target lesion) according to RECIST v1.1 assessed by conventional CT scan. Exclusion Criteria: \* Patients having out of range laboratory values for kidney function and blood markers as defined in the study protocol \* Patients with inadequate hepatic function \* Unmanageable urinary tract obstruction or urinary incontinence Other protocol-defined inclusion/exclusion criteria may apply. Netherlands #### Novartis Investigative Site Recruiting Groningen,Provincie Groningen,9728 nz,Netherlands ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ +41613241111](tel:+41613241111) Email: